Shares of Biogen Inc. BIIB advanced 5.65% to $120.49 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 9.52% to 5,456.90 and ...

Shares in major U.S. and European pharmaceutical companies fell sharply Wednesday, underperforming a broader market downturn, after U.S. President Donald Trump said the country would soon impose “a ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Morgan Stanley lowered the firm’s price target on Biogen (BIIB) to $152 from $157 and keeps an Equal Weight rating on the shares. The firm ...

Shares of Biogen Inc. BIIB slipped 4.31% to $114.05 Tuesday, on what proved to be an all-around poor trading session for the ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by Argus from a “buy” rating to a “hold” rating in a report released on ...

Fintel reports that on April 4, 2025, Argus Research downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

Biogen (NasdaqGS:BIIB) recently received Fast Track designation from the FDA for its Alzheimer's therapy, BIIB080, signaling a significant advancement in its drug development ambitions. However, ...

The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease ...

Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...

Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting ...